VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 ‘Multi-Blockbusters’ - Yahoo Finance

NVO tumbled about 8% as its Capital Markets Day failed to convince investors despite plans for more than five “multi-blockbusters” by 2030.Viking’s injectable VK2735 produced up to 14.7% weight loss, while its oral formulation delivered 12.2% after 13 weeks.Structure’s oral Aleniglipron achieved up to 16.2% weight loss at 72 weeks, while Altimmune advanced Pemvidutide into Phase 3 for MASH.Shares of smaller obesity players jumped on Monday after Novo Nordisk (NVO) said that it could pursue larger acquisitions while targeting more than five “multi-blockbuster” launches by 2030.Viking Therapeutics (VKTX) shares gained nearly 4%, Structure Therapeutics (GPCR) rose more than 5% and Altimmune (ALT) edged nearly 1% higher. Novo Nordisk’s U.S.-listed shares, meanwhile, tumbled about 8% after its Capital Markets Day failed to win over investors. Novo’s shares sank despite its blockbuster ambitions and encouraging CagriSema results.